Clinical efficacy of levamisole in the treatment of primary nephrosis in children.
The purpose of the study was to evaluate the efficacy and the toxicity of levamisole given for 1 year to 16 children suffering from minimal change primary nephrosis who were relapsing frequently. The overall results showed that under levamisole the relapse rate decreased by 55% and the steroid requirements by 50%. After cessation of levamisole administration, most children (11/16) relapsed again. A second course of levamisole treatment reduced the relapse rate significantly once again. At the dosage of 2.5 mg/kg given every other day for 1 year or more, no side effects of levamisole does not cure nephrosis but reduces the incidence of relapses for the period it is administered. It also reduces the steroid requirements without any important side effects.
Mongeau
J G
JG
Department of Pediatrics, Ste-Justine Hospital, Montreal, Quebec, Canada.
Robitaille
P O
PO
Roy
F
F
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007978:Levamisole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009402:Nephrosis, Lipoid / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D012008:Recurrence
D007978:Levamisole; D011241:Prednisone